Tranexamic Acid: Clinical Indications, Dosing, and Safety
Primary Indications
Tranexamic acid should be administered in major trauma with active bleeding or risk of significant hemorrhage, postpartum hemorrhage, and major surgical procedures to reduce mortality and blood loss. The evidence is strongest for trauma and obstetric hemorrhage, where early administration saves lives 1, 2, 3.
Trauma and Major Hemorrhage
For bleeding trauma patients, administer 1 g tranexamic acid IV over 10 minutes as early as possible, followed by 1 g infused over 8 hours 1. This regimen reduces all-cause mortality (relative risk 0.91) and hemorrhage-related mortality (relative risk 0.85) 1, 2.
Critical timing consideration: Tranexamic acid MUST be given within 3 hours of injury 1. The benefit decreases by 10% for every 15-minute delay 2. Administration beyond 3 hours shows no benefit and may increase mortality from hemorrhage (RR 1.44) 1. Pre-hospital administration is recommended when feasible 1.
The CRASH-2 trial demonstrated these mortality benefits in over 20,000 trauma patients, with effects consistent across injury severity levels 1, 2. Recent evidence suggests higher doses (up to 3 g total) may benefit hypotensive patients, though the standard 2 g regimen remains most widely validated 2.
Postpartum Hemorrhage
For postpartum hemorrhage (blood loss >500 mL vaginal or >1000 mL cesarean), give 1 g tranexamic acid IV over 10 minutes, with a second 1 g dose if bleeding continues after 30 minutes or restarts within 24 hours 3. This should be administered regardless of whether bleeding is from uterine atony or genital tract trauma 3. The same 3-hour window applies—give as soon as possible after birth, as efficacy decreases with delay 3.
Surgical Applications
In major cardiac and orthopedic surgery, tranexamic acid reduces blood loss and transfusion requirements without increasing thrombotic events 4, 5. For surgery, typical dosing is 10-15 mg/kg loading dose followed by 1-5 mg/kg/hour maintenance infusion 6. Recent evidence supports a 15 mg/kg bolus over 15 minutes with 7.5 mg/kg/hour maintenance for 2 hours in patients with normal renal function 7.
Anticoagulated Patients
Tranexamic acid should be administered to bleeding patients on anticoagulants using the same indications as non-anticoagulated patients 8. The drug acts on different hemostatic targets than anticoagulants, and there is no evidence its efficacy is altered by anticoagulant presence 8.
Pediatric Dosing
For pediatric trauma and surgery, administer 10-30 mg/kg loading dose followed by 5-10 mg/kg/hour maintenance infusion 9, 10. The FDA-approved regimen for hemophilia patients undergoing dental extraction is 10 mg/kg IV immediately before extraction, then 10 mg/kg 3-4 times daily for 2-8 days 11.
For post-tonsillectomy hemorrhage, nebulized tranexamic acid (500 mg in 5 mL saline) is increasingly used for active bleeding, with IV tranexamic acid reserved for higher-volume or uncontrolled bleeding 12.
Renal Dose Adjustment
Tranexamic acid is 90% renally excreted and requires dose reduction in renal impairment 11, 5:
- Serum creatinine 1.36-2.83 mg/dL: 10 mg/kg twice daily
- Serum creatinine 2.83-5.66 mg/dL: 10 mg/kg once daily
- Serum creatinine >5.66 mg/dL: 10 mg/kg every 48 hours OR 5 mg/kg every 24 hours
For major surgery in chronic kidney disease, reduce maintenance infusion to 5 mg/kg/hour (versus 7.5 mg/kg/hour for normal function) 7.
Contraindications
Absolute contraindications 11:
- Active intravascular clotting or disseminated intravascular coagulation
- Subarachnoid hemorrhage (risk of cerebral edema and infarction)
- Severe hypersensitivity to tranexamic acid
Relative contraindications and cautions 4, 11:
- History of thromboembolic disease (use only when bleeding risk exceeds thrombotic risk)
- Concomitant prothrombotic medications (Factor IX concentrates, hormonal contraceptives)
- Massive hematuria with risk of ureteric obstruction
- Renal impairment (requires dose adjustment, not contraindication)
Administration and Monitoring
Infuse no faster than 1 mL/minute to avoid hypotension 11. Tranexamic acid is for intravenous use ONLY—inadvertent intrathecal administration causes seizures and cardiac arrhythmias 11.
The drug can be mixed with most IV solutions (electrolytes, dextrose, amino acids, dextran) and heparin, but should NOT be mixed with blood or penicillin-containing solutions 11.
No routine laboratory monitoring is required 1, 4. However, in settings where available, viscoelastic testing (TEG/ROTEM) can identify hyperfibrinolysis and guide therapy 6.
Safety Profile and Adverse Events
Tranexamic acid does not increase thromboembolic risk at standard doses 1, 4, 5. The CRASH-2 trial showed lower rates of myocardial infarction with tranexamic acid versus placebo 1. A meta-analysis of 125,550 participants found no increased thrombotic complications 4.
Dose-dependent seizure risk exists, particularly in cardiac surgery with high doses 1, 13. Maximum total dose should not exceed 100 mg/kg, especially in patients over 50 years 5, 13. The thromboembolic risk rises markedly at doses ≥4 g (hazard ratio 5.33) 14.
Common adverse effects include nausea, vomiting, diarrhea, dizziness, and hypotension (if infused too rapidly) 11. Visual disturbances and allergic reactions are rare but require immediate discontinuation 11.
Special Populations Not Recommended
Routine tranexamic acid use is NOT recommended for 15:
- Cirrhosis patients undergoing invasive procedures (insufficient evidence, potential harm)
- Non-traumatic intracerebral hemorrhage on anticoagulants (TICH-NOAC showed no benefit) 8
- Upper gastrointestinal hemorrhage (HALT-IT trial showed no benefit) 8
For dental procedures in cirrhosis patients, topical tranexamic acid on gauze shows no benefit over standard care 15.
Clinical Pitfalls
The most critical error is delayed administration in trauma—every 15 minutes of delay reduces benefit by 10%, and administration after 3 hours may cause harm 1, 2. Pre-hospital protocols should include tranexamic acid for suspected major hemorrhage 1.
Avoid excessive dosing, particularly in cardiac surgery and elderly patients, where neurotoxicity risk increases 5, 13. In renal impairment, failure to adjust dosing leads to drug accumulation and increased adverse events 11, 7.
Never administer intrathecally—this route causes seizures and is potentially fatal 11. Ensure proper labeling and administration protocols to prevent route errors.